Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $38

Benzinga Newsdesk www.benzinga.com Positive 91.1%

Neg 0% Neu 0% Pos 91.1%

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $36 to $38.